Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy C Rawstron

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Cytometry. Part B, Clinical Cytometry|January 27, 2015
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reportingMaria Arroz, Neil Came, Pei Lin, et al.
Clinical Lymphoma & Myeloma|August 2, 2006
Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significanceRebecca A Rollett, Elizabeth J Wilkinson, David Gonzalez, et al.
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Blood|September 20, 2002
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansionAndy C Rawstron, Martin R Yuille, Julie Fuller, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2019
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal DiseasesMd Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trialDena R Howard, Talha Munir, Lucy McParland, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
British Journal of Haematology|November 1, 2007
Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experienceAndy C Rawstron, Richard A Jones, Carol Ferguson, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Cytometry. Part B, Clinical Cytometry|January 27, 2015
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reportingMaria Arroz, Neil Came, Pei Lin, et al.
Clinical Lymphoma & Myeloma|August 2, 2006
Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significanceRebecca A Rollett, Elizabeth J Wilkinson, David Gonzalez, et al.
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Blood|September 20, 2002
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansionAndy C Rawstron, Martin R Yuille, Julie Fuller, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2019
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal DiseasesMd Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trialDena R Howard, Talha Munir, Lucy McParland, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
British Journal of Haematology|November 1, 2007
Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experienceAndy C Rawstron, Richard A Jones, Carol Ferguson, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
Pageof 8